Jade Biosciences Announces $135 Million Private Placement

Core Viewpoint - Jade Biosciences, Inc. has announced a PIPE financing agreement expected to generate approximately $135 million in gross proceeds to fund its research and development efforts for autoimmune disease therapies [1][4]. Financing Details - The PIPE financing involves the sale of 13,368,164 shares of common stock at a price of $9.14 per share and pre-funded warrants for 1,402,092 shares at a price of $9.1399 per warrant [3]. - The transaction is anticipated to close on or about October 8, 2025, pending customary closing conditions [3]. Investor Participation - The financing attracted both new and existing investors, including notable firms such as Janus Henderson Investors, Fairmount, and RA Capital Management [2]. Use of Proceeds - The net proceeds from the PIPE financing will be utilized for research and development, general corporate expenses, and working capital needs, with expectations to fund operations into the first half of 2028 [4]. Company Overview - Jade Biosciences is focused on developing therapies for autoimmune diseases, with its lead candidate, JADE101, currently in a Phase 1 clinical trial for immunoglobulin A nephropathy (IgAN) [7]. - The company also has a second candidate, JADE201, and an undisclosed antibody discovery program in preclinical development [7].